Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized placebo-controlled study of deucravacitinib in pediatric moderate to severe plaque psoriasis
jRCT2051220141Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2023
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of deucravacitinib in plaque psoriasis (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: PASI 75 at Week 16 and sPGA response at Week 16. Started Jan 2023; status: recruiting.
02
Drugs
deucravacitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on jRCT2051220141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051220141.